Carbamazepine Tablet, Extended Release
NDC Package 70771-1468-4

11-digit billing NDC: 70771146804
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Carbamazepine tablets is carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. This formulation utilizes a tablet, extended release delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1468 and is authorized under FDA application ANDA205571.

Identification & Billing

NDC Package Code
70771-1468-4
Package Description
10 BLISTER PACK in 1 CARTON / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
70771-1468
11-Digit Billing Format
70771146804
RxNorm Crosswalk
  • RxCUI: 199378 - carBAMazepine 100 MG 12HR Extended Release Oral Tablet
  • RxCUI: 199378 - 12 HR carbamazepine 100 MG Extended Release Oral Tablet
  • RxCUI: 199378 - carbamazepine 100 MG 12 HR Extended Release Oral Tablet
  • RxCUI: 402505 - carBAMazepine 200 MG 12HR Extended Release Oral Tablet
  • RxCUI: 402505 - 12 HR carbamazepine 200 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Carbamazepine
Non-Proprietary Name
Carbamazepine
Substance Name
Carbamazepine
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
CARBAMAZEPINE 100 mg/1
Pharmacologic Class
Usage Information
Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. Likewise, on theoretical grounds its use with monoamine oxidase (MAO) inhibitors is not recommended. Before administration of carbamazepine, MAO inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits.Coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated.

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA205571
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-12-2019
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70771-1468). Click a package code to view its specific billing and regulatory data.

70771-1468-1
100 TABLET, EXTENDED RELEASE in 1 BOTTLE
70771-1468-3
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
70771-1468-9
90 TABLET, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70771-1468-4 identifies a specific commercial package of 10 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack of Carbamazepine, a human prescription drug labeled by Zydus Lifesciences Limited. This tablet, extended release is formulated for oral use and contains carbamazepine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on March 12, 2019. The current certification is valid through December 31, 2027.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771146804. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70771-1468-4
11-Digit CMS (5-4-2)
70771-1468-04

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.